Corpus Intelligence IC Memo — THE BROOKLYN HOSPITAL CENTER 2026-04-26 15:12 UTC
IC Memo — THE BROOKLYN HOSPITAL CENTER
Investment Committee Memorandum | NY | 257 beds | Grade C | EBITDA uplift $29.7M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

THE BROOKLYN HOSPITAL CENTER

CCN 330056 | KINGS, NY | 257 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

THE BROOKLYN HOSPITAL CENTER is a 257-bed suburban community hospital in KINGS, NY with $403.1M in net patient revenue and a -11.4% operating margin. The hospital serves a payer mix of 19.9% Medicare, 8.5% Medicaid, and 71.7% commercial.

Thesis: Undervalued. Our ML models identify $29.7M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -11.4% to -4.0% (+736bps).

Net Revenue HCRIS$403.1M
Current EBITDA COMPUTED$-45.8M
Operating Margin COMPUTED-11.4%
Occupancy HCRIS75.0%
Revenue / Bed COMPUTED$1.6M
Net-to-Gross HCRIS22.1%
Distress Probability ML42.2%

2. Market Context & Competitive Position

196
NY Hospitals
-17.5%
State Median Margin
97
Comparable Hospitals

NY has 196 Medicare-certified hospitals with a median operating margin of -17.5%. The target's margin of -11.4% places it above the state median. Among 97 size-comparable peers (128-514 beds), the median margin is -17.8%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (128-514), prioritizing same-state peers. 97 hospitals in the comp set.

HospitalStateBedsRevenueMargin
THE BROOKLYN HOSPITAL CENTER (Target)NY257$403.1M-11.4%
MEMORIAL HOSPITAL FOR CANCER ANY514$4.34B-32.5%
LENOX HILL HOSPITALNY415$1.32B-35.1%
JACOBI MEDICAL CENTERNY440$1.14B-16.8%
HOSPITAL FOR SPECIAL SURGERYNY200$1.12B-29.3%
ROCHESTER GENERAL HOSPITALNY470$1.05B-27.9%
NYC HEALTH+HOSPITAL/KINGS COUNNY381$1.03B-15.0%
NEWYORK-PRESBYTERIAN/QUEENSNY476$890.1M-50.0%
ST. FRANCIS HOSPITALNY364$889.3M2.0%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $29.7M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$8.5M+210bp18mo
Cost to Collect4.5%2.5%$8.1M+200bp12mo
Denial Rate Reduction12.0%6.5%$8.0M+198bp12mo
A/R Days Reduction5200.0%3800.0%$4.9M+122bp9mo
Clean Claim Rate88.0%96.0%$258K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$8.5M
Cost to Collect
$8.1M
Denial Rate Reduction
$8.0M
A/R Days Reduction
$4.9M
Clean Claim Rate
$258K
Total EBITDA Uplift$29.7M
Current EBITDA$-45.8M
+ RCM Uplift+$29.7M
Pro Forma EBITDA$-16.2M
Current Margin-11.4%
Pro Forma Margin-4.0%
WC Released (1x)$15.5M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-70.5M$-5.7M0.00x-100.0%
Base (11x exit)10.0x11.0x$-70.5M$-29.1M0.00x-100.0%
Bull Case9.0x11.0x$-63.5M$45.9M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-63.5M$31.3M0.00x-100.0%
Bear Case11.0x10.0x$-77.6M$-131.1M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-77.6M$-169.4M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 97 hospitals with 128-514 beds
  • Same-state prioritization (n=98)
  • Comp margins: P25=-28.2% / P50=-17.8% / P75=-9.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.